ALIGNMENT HEALTHC.DL-,001 Aktie

Alignment Healthcare’s shares closed at $12.68, marking a new 52-week low; year-to-date the stock is down 31.85%. InvestingPro estimates the fair value at $17.04, classifying the stock as undervalued. For Q2 the company beat adjusted EPS with $0.17 (expectation $0.13), slightly missed revenue at $1.3bn, but reported 32% revenue growth, 31% membership growth and adjusted EBITDA of $68m (+48%). Raymond James downgraded its rating to "Outperform," citing lower earnings visibility due to expansion and higher capital spending, while Alignment raised its full-year guidance. » More on de.investing.com

Alignment Healthcare reported second-quarter net income of $36.6 million, more than double year-ago levels, as medical costs for its Medicare Advantage members moderated. The company’s medical benefit ratio improved to about 86%, marking a second consecutive quarter of decline, while total revenue rose over 31% to $1.3 billion. Medicare Advantage membership grew 31% to 294,100 members. Management cited benefits from investments in clinical models, AI-enabled capabilities and operational infrastructure supporting profitable growth. » More on forbes.com

Shares of Alignment Healthcare recover after a roughly 17% drop following a whistleblower lawsuit, rising about 6% in midday trading. KeyBanc analyst Matthew Gillmor affirms an "overweight" rating and a $28 price target, calls the market reaction excessive and views the sell-off as a buying opportunity. Alignment categorically denied the allegations and points to a prior independent accounting review that found the claims unfounded. Support also came from a positive overall market and gains by competitors in the Medicare Advantage segment, while legal uncertainty limits a full recovery for now. » More on de.investing.com